Avrobio (Avrobio) Cash-to-Debt : 111.64 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Avrobio Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Avrobio's cash to debt ratio for the quarter that ended in Dec. 2023 was 111.64.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Avrobio could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Avrobio's Cash-to-Debt or its related term are showing as below:

AVRO' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.62 Med: No Debt Max: No Debt
Current: 111.64

During the past 8 years, Avrobio's highest Cash to Debt Ratio was No Debt. The lowest was 5.62. And the median was No Debt.

AVRO's Cash-to-Debt is ranked better than
79.79% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs AVRO: 111.64

Avrobio Cash-to-Debt Historical Data

The historical data trend for Avrobio's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Avrobio Cash-to-Debt Chart

Avrobio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

12.68

5.62

111.64

Avrobio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															5.62	3.95	52.30	60.41	111.64

Competitive Comparison of Avrobio's Cash-to-Debt

For the Biotechnology subindustry, Avrobio's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avrobio's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avrobio's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Avrobio's Cash-to-Debt falls into.

Avrobio Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Avrobio's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	98.02	/	(0.878	+	0)
	=	111.64

Avrobio's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	98.02	/	(0.878	+	0)
	=	111.64

Avrobio (NAS:AVRO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Avrobio Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Avrobio's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Avrobio (Avrobio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avrobio Inc (NAS:AVRO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Technology Square, Sixth Floor, Cambridge, MA, USA, 02139

Website

https://www.avrobio.com

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.

Executives

Azadeh Golipour	officer: Chief Technology Officer	ONE KENDALL SQUARE, BLD. 300 - SUITE 201, CAMBRIDGE MA 02139
Essra Ridha	officer: Chief Medical Officer	C/O AVROBIO, INC., ONE KENDALL SQUARE, BLDG 300 - SUITE 201, CAMBRIDGE MA 02139
Philip J. Vickers	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Christopher Mason	officer: Chief Scientific Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Phillip B. Donenberg	director	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Diana Escolar	officer: Chief Medical Officer	C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Gail M Farfel	director	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Deanna M Petersen	officer: Chief Business Officer	45 FIRST AVENUE, WALTHAM MA 02451
Geoffrey Mackay	director, officer: See Remarks	C/O AVROBIO, INC., ONE KENDALL SQ, BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Christopher Paige	director	C/O AVROBIO INC, ONE KENDALL SQ, BLDG 300, STE 201, CAMBRIDGE MA 02139
Atlas Venture Fund X, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, Llc	other: See Remarks	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, L.p.	other: See Remarks	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund I, L.p.	other: See Remarks	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Bruce Booth	director	890 WINTER STREET, SUITE 320, WALTHAM MA 02451